ADMA Biologics, Inc. announced the Company has executed a definitive credit agreement with Ares Management credit funds ("Ares") for $135 million in total senior secured credit facilities, including a $72.5 million asset-backed revolving credit facility and a $62.5 million term loan. The proceeds of the senior secured credit facilities were fully drawn at closing and used, along with existing cash, to repay all obligations under the prior Hayfin Capital Management senior secured credit facility.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.55 USD | +1.71% | +4.47% | +44.91% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.91% | 1.52B | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.35B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- ADMA Stock
- News ADMA Biologics, Inc.
- ADMA Biologics, Inc. Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management